ORIC Pharmaceuticals
Advances two Phase 3 oncology candidates targeting drug-resistant prostate and lung cancers.
$13.24
After-hours close+0.01 (+0.08%)
At close$13.23(−3.71%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.40 | — | — |
| Aug 2026 | −$0.36 | −$0.38 | −5.7% |
| May 2026 | −$0.31 | −$0.34 | −9.7% |
| Feb 2026 | −$0.34 | −$0.30 | +11.8% |
| Nov 2025 | −$0.41 | −$0.33 | +19.5% |
The latest year is open to everyone — the 26 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Apr 2020 | |||
| Sep 2019 | |||
| Jun 2019 | |||
| Mar 2019 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 12, 2026 | −$0.40 | — | — | — | — | — |
| Aug 3, 2026 | −$0.36 | −$0.38 | −5.7% | — | — | — |
| May 4, 2026 | −$0.31 | −$0.34 | −9.7% | — | — | — |
| Feb 23, 2026 | −$0.34 | −$0.30 | +11.8% | — | — | — |
| Nov 13, 2025 | −$0.41 | −$0.33 | +19.5% | — | — | — |
The latest year is open to everyone — the 26 quarters behind it read with an account. Sign in | ||||||
| Aug 12, 2025 | ||||||
| May 5, 2025 | ||||||
| Feb 18, 2025 | ||||||
| Nov 12, 2024 | ||||||
| Aug 12, 2024 | ||||||
| May 6, 2024 | ||||||
| Mar 11, 2024 | ||||||
| Nov 6, 2023 | ||||||
| Aug 10, 2023 | ||||||
| May 8, 2023 | ||||||
| Mar 16, 2023 | ||||||
| Nov 7, 2022 | ||||||
| Aug 11, 2022 | ||||||
| May 9, 2022 | ||||||
| Mar 21, 2022 | ||||||
| Nov 8, 2021 | ||||||
| Aug 10, 2021 | ||||||
| May 6, 2021 | ||||||
| Mar 23, 2021 | ||||||
| Nov 5, 2020 | ||||||
| Aug 5, 2020 | ||||||
| May 20, 2020 | ||||||
| Apr 23, 2020 | ||||||
| Sep 30, 2019 | ||||||
| Jun 30, 2019 | ||||||
| Mar 31, 2019 | ||||||